CHASING A RARITY: A RETROSPECTIVE SINGLE CENTRE EVALUATION OF PROGNOSTIC FACTORS IN GLIOSARCOMA
PO-1160
Abstract
CHASING A RARITY: A RETROSPECTIVE SINGLE CENTRE EVALUATION OF PROGNOSTIC FACTORS IN GLIOSARCOMA
Authors: Muemtaz Koeksal1, Cas Dejonckheere1, Alexander Böhner2, Ulrich Herrlinger3, Hartmut Vatter4, Frank Anton Giordano1
1University Hospital, Department of Radiation Oncology, Bonn, Germany; 2University hospital, Department of Radiology, Bonn, Germany; 3University Hospital, Division of Clinical Neuro-Oncology, Department of Neurology, Bonn, Germany; 4University Hospital, Department of Neurosurgery, Bonn, Germany
Show Affiliations
Hide Affiliations
Purpose or Objective
Primary gliosarcoma (GS) is a rare variant of IDH-wildtype
glioblastoma multiforme. We performed a single center analysis to identify
prognostic factors.
Material and Methods
We analysed the records of 26 patients newly
diagnosed with primary WHO Grade IV GS. Factors of interest were clinical and
treatment data, as well as molecular markers, time to recurrence, and time to
death.
Results
The median follow-up was 9 months (range from 5 to 21
months). Low symptom burden at the time of diagnosis was associated with longer
PFS (P = 0.023) and OS (P = 0.018). The median OS in the entire
cohort was 12 months. Neither MGMT
promoter hypermethylation nor adjuvant temozolomide therapy influenced survival,
in consistency with some previous reports.
Conclusion
In this retrospective study, patients exhibiting low
symptom burden at diagnosis showed improved survival. None of the other factors
analysed were associated with altered outcome.